Brass particulates have been identified in the primary container. All Pallimed Pharmacy sterile compound products dispensed since Jan. 1, 2013 are being recalled due to visible particulates.

A product recall has been issued due to the presence of hydroxythiohomosildenafil, a sildenafil analogue, in ROCK anti-seizure medication.

The Veria IQ meter has been discovered to turn off, rather than display high glucose warning when readings are greater than 300 mg/dL. Recall of One Touch Verio IQ Blood Glucose Meter.

The Louisiana Drug Information Center (DIC), which became operational in 1995, is located on the first floor of the University Hospital in the University of Louisiana at Monroe College of Pharmacy. The DIC exists to conduct research for the advancement of drug information and pharmacy practice. The service component makes up the largest portion of the DIC operation and includes providing health care professionals with comprehensive drug information support services. These services include written and verbal drug information, on-site professional consultations, telephonic consultations, written material on drug therapy, and mini-symposia. The DIC provides drug information to practicing pharmacists, pharmacy residents, health care professionals, students, the general public, and other organizations and agencies within the state of Louisiana.

Toxicology

In the OVERCOME trial, enalapril and carvedilol may prevent left ventricular systolic dysfunction related to treatment with intensive chemotherapy. A study found that the multiple sclerosis drug, Acorda, might also help stroke patients with impaired motor function.

FDA Approves First Heptavalent Botulism Antitoxin

Warner Chilcott has gained approval to add a 200 mg delayed release contraceptive.

Valproate Therapy During Pregnancy Linked to Autism

HIV Vaccine Study Halted by Investigators

SSRI Therapy Around Time of Surgery Tied to Increased Complications

A post hoc analysis of the REDUCE study evaluated the possible benefit of treating asymptomatic or mildly symptomatic men with dutasteride for benign prostatic hyperplasia. The study found that dutasteride associated with slower progression of benign prostatic hyperplasia.

Recall of Intravenous Immune Globulin

FDA Lowers Age for Plan B Access to 15 Years

Recall of Affirm XL, Dietary Supplement

Valproate Therapy During Pregnancy Linked to Autism

FDA Approves Sitavig

New Higher Strength, Fast-Acting Capsules for Peptic Ulcer Disease Approved

Dutasteride Associated With Slower Progression of BPH

Recall of Balanced Solutions Sterile Compounded

Sterility Assurance Concerns Results in Recall of ApotheCure Products

Sterility Assurance Concerns Leads to Recall of Nora Apothecary Products

Saratoga Therapeutics LLC recalled 900 bottles of ebA Multivitamin Supplement due to undeclared milk components, though the company claimed that the product was the same as another product, the Company was told that the product was not the same.

Piperacillin/Tazobactam for Injection Recalled

Kadcyla (ado-trastuzumab emtansine) may appear in some electronic systems, which could potentially lead to medication errors.

Sign Up to Receive Medwatch Alert Emails

The service component makes up the largest portion of the DIC operation and includes providing health care professionals with comprehensive drug information support services. These services include written and verbal drug information, on-site professional consultations, telephonic consultations, written material on drug therapy, and mini-symposia. The DIC provides drug information to practicing pharmacists, pharmacy residents, health care professionals, students, the general public, and other organizations and agencies within the state of Louisiana.

Seizure Medication

The antitoxin neutralizes all seven known botulinum nerve toxin serotypes and will be stored in the Strategic National Stockpile for emergency preparedness.

New Diabetes Algorithm: American Association Of Clinical Endocrinologists

Effective Treatment for HIV Vaccine Study Halted by Investigators

SSRI Therapy Around Time of Surgery Tied to Increased Complications

A post hoc analysis of the REDUCE study evaluated the possible benefit of treating asymptomatic or mildly symptomatic men with dutasteride for benign prostatic hyperplasia. The study found that dutasteride associated with slower progression of benign prostatic hyperplasia.

Recall of Intravenous Immune Globulin

FDA Lowers Age for Plan B Access to 15 Years

Recall of Affirm XL, Dietary Supplement

Valproate Therapy During Pregnancy Linked to Autism

HIV Vaccine Study Halted by Investigators

SSRI Therapy Around Time of Surgery Tied to Increased Complications

A post hoc analysis of the REDUCE study evaluated the possible benefit of treating asymptomatic or mildly symptomatic men with dutasteride for benign prostatic hyperplasia. The study found that dutasteride associated with slower progression of benign prostatic hyperplasia.